EDU 03 Difficult Cases in Breast Cancer
|
1.25 |
|
|
|
Panel 02 A Roadmap for Recruiting Medical Students into Radiation Oncology during a Period of Waning Interest
|
1.25 |
|
|
|
PRO 03 Head and Neck Cancer: Case Based Discussion
|
1.25 |
|
|
|
International Session 01 Latin America ASTRO - Part 1
|
1.75 |
|
|
|
PRO 04 Gastrointestinal Cancer: Case Based Discussion
|
1.25 |
|
|
|
International Session 02 RUSSCO-ASTRO Joint Panel Session — Evidenced-based Management of Head and Neck Malignancies: Global Contexts and International Comparisons
|
1.25 |
|
|
|
PRO 01 Central Nervous System: Case Based Discussion
|
1.25 |
|
|
|
Joint Session 01 American Association for the Study of Liver Diseases (AASLD) — ASTRO Joint Session on the Multidisciplinary Management of Hepatocellular Carcinoma: Guidelines, Practicalities and a Tumor Board
|
1.25 |
|
|
|
EDU 02 Radiation/Immunotherapy Combinations in Localized Lung Cancer
|
1.25 |
|
|
|
PRO 05 Lung Cancer: A Case Based Discussion
|
1.25 |
|
|
|
EDU 01 Challenging Cases in Palliative Care
|
1.25 |
|
|
|
PRO 02 Lymphoma: Case Based Discussion
|
1.25 |
|
|
|
eContouring 01 eContouring for Lung Cancer
|
1.25 |
|
|
|
SS 02 Physics 01 - Best of Physics
|
1.25 |
|
|
|
SS 05 GU 02 - Salvage Radiotherapy and Systemic Therapy
|
1.25 |
|
|
|
SS 07 Biology 03 - Target Discovery
|
1.25 |
|
|
|
SS 03 Breast 01 - Techniques and Toxicities
|
1.25 |
|
|
|
SS 01 Biology 01 - Biology Special Session: Prediction and Monitoring of Radiation Response
|
1.25 |
|
|
|
SS 04 Biology 02 - Oncogenisis and Oncoprogression Signatures
|
1.25 |
|
|
|
QP 01 Digital Health Innovation/Informatics 1 - Clinical Applications of Artificial Intelligence Session 1
|
1 |
|
|
|
QP 02 GU 01 - Fractionation, Biology and Prognosis
|
1 |
|
|
|
QP 03 Education & Professional Development 01
|
1 |
|
|
|
QP 04 Pediatrics 01 - Focus on Pediatric Long Term Outcomes and Toxicity
|
1 |
|
|
|
SH 02 Science Highlights - Health Services Research/Global Oncology
|
0.5 |
|
|
|
SH 05 Science Highlights - (GU) Genitourinary
|
0.5 |
|
|
|
SH 01 Science Highlights - (CNS) Central Nervous System
|
0.5 |
|
|
|
SH 04 Science Highlights - Lung Cancer/Thoracic Malignancies
|
0.5 |
|
|
|
SH 06 Science Highlights - Radiation and Cancer Biology
|
0.5 |
|
|
|
SH 03 Science Highlights - Breast Cancer
|
0.5 |
|
|
|
SS 06 CNS 01 - Gliomas (Low Grade, High Grade)
|
1.25 |
|
|
|
Workshop 02 ACGME - Review Committee Update and Accreditation Info You Need for Your Program
|
1.25 |
|
|
|
ST 01 Storytelling 01 - Global and Domestic Prostate Cancer Disparities: Biology, Social Determinants, and Other Factors
|
1 |
|
|
|
CB 01 Cancer Breakthroughs 1 - Takeaways from the Major Oncology Meetings of 2020: Featuring AACR and RRS
|
1 |
|
|
|
International Session 01 Latin America ASTRO - Part 2
|
1.5 |
|
|
|
SH 08 Science Highlights - Gynecological
|
0.5 |
|
|
|
SH 09 Science Highlights - (H&N) Head and Neck Cancers
|
0.5 |
|
|
|
SH 10 Science Highlights - Hematologic
|
0.5 |
|
|
|
SH 11 Science Highlights - Palliative Care
|
0.5 |
|
|
|
SH 12 Science Highlights - Patient Safety
|
0.5 |
|
|
|
SH 13 Science Highlights - Pediatric Cancer
|
0.5 |
|
|
|
SH 14 Science Highlights - Radiation and Cancer Physics
|
0.5 |
|
|
|
SH 15 Science Highlights - Sarcoma and Cutaneous Tumors
|
0.5 |
|
|
|
Panel 01 Quality Payment Program: RO Model and MIPS 2021
|
1.25 |
|
|
|
EDU 09 Controversies in Brain Metastasis Management: Interactive Case-Based Discussion
|
1.25 |
|
|
|
PRO 08 Prostate Cancer: Case Based Discussion
|
1.25 |
|
|
|
Panel 04 Evolving Treatment Paradigms for Locally Advanced Rectal Cancer: An ASTRO Evidence-Based Clinical Practice Guideline
|
1.25 |
|
|
|
PRO 07 ASTRO Scientific Review 2020
|
1.25 |
|
|
|
Panel 03 Global Management of Nasopharyngeal Carcinoma: Integrating Recent Data into Clinical Practice and Tackling Topics of Uncertainty
|
1.25 |
|
|
|
PRO 09 Gynecologic Cancer: Case Based Discussion
|
1.25 |
|
|
|
PRO 06 Socioeconomic Update
|
1.25 |
|
|
|
PRO 10 Breast Cancer: Case Based Discussion
|
1.25 |
|
|
|
EDU 06 High Yield Quality Assurance in Your Clinic: Keeping Clinic Safe for the Rest of Us
|
1.25 |
|
|
|
eContouring 02 eContouring for Oligometastatic Disease - Liver
|
1.25 |
|
|
|
SS 09 GU 03 - Novel Approaches to Genitourinary Malignancies
|
1.25 |
|
|
|
SS 10 Physics 03 - Special Session 1 - Artificial Intelligence in Radiomics and Outcome Predictions
|
1.25 |
|
|
|
SS 11 Palliative Care 01 - Improving the Quality of Palliative Radiotherapy
|
1.25 |
|
|
|
SS 14 Physics 04 - Special Session 2 - Artificial Intelligence for Imaging and Treatment Planning
|
1.25 |
|
|
|
SS 12 Pediatrics 02 - Maximizing Cure and Minimizing Toxicity for Pediatric Cancer
|
1.25 |
|
|
|
SS 13 Biology 04 - DNA Damage and Response
|
1.25 |
|
|
|
QP 05 Physics 02 - Practical Artificial Intelligence Applications for Patient Modeling, Treatment Planning, Image Guidance and Response Assessment
|
1 |
|
|
|
QP 06 Sarcoma and Extremity Skin Malignancies
|
1 |
|
|
|
QP 08 Lung 01 - Cardiac Effects of Radiotherapy
|
1 |
|
|
|
QP 09 Hematologic 1 - Survivorship: Improving the Benefit-Morbidity Balance of Radiotherapy in Hematologic Malignancies
|
1 |
|
|
|
PS 02 Presidential Symposium Segment II: Clinical Challenges and Potential Solutions
|
1 |
|
|
|
SS 08 Breast 02 - Biology and Outcomes
|
1.25 |
|
|
|
QP 07 HSR/Global Oncology 1 - Global Oncology and Health Disparities
|
1 |
|
|
|
Storytelling 03 COVID-19 Session
|
1.5 |
|
|
|
International Session 03 ASTRO/ESTRO Joint Session
|
1.25 |
|
|
|
Storytelling 02 A Stitch in Time Saves Nine
|
0.5 |
|
|
|
PS Introduction Presidential Symposium Introduction
|
0.5 |
|
|
|
PS 01 Presidential Symposium Segment I: Strategic initiatives
|
1 |
|
|
|
PS 03 Presidential Symposium Segment III: Partners and Collaborators
|
1 |
|
|
|
PS 04 Presidential Symposium Segment IV: A Practical Roadmap for Action
|
1 |
|
|
|
PS 05 Presidential Symposium Segment V: Summary and Conclusion
|
0.5 |
|
|
|
CB 02 Cancer Breakthroughs 2 - Takeaways from the Major Oncology Meetings of 2020: Featuring ESTRO
|
0.5 |
|
|
|
EDU 12 Patient Reported Outcomes: Incorporation into Your Work Flow
|
1.25 |
|
|
|
Special Session 03 Clinical Practice Guideline Highlight Session: Implementing New Recommendations
|
1.25 |
|
|
|
Joint Session 02 The Impact of Neoadjuvant Therapeutics on the Surgical, Medical Oncological, and Irradiation Approaches to Breast Cancer Treatment
|
1.25 |
|
|
|
EDU 08 Breast-Cancer Related Lymphedema: Risk Factors, Diagnosis and Management
|
1.25 |
|
|
|
EDU 17 Lung Cancer Difficult Cases: Thoracic Re-Treatment
|
1.25 |
|
|
|
EDU 07 Introduction to Big Data Analytics and Machine Learning
|
1.25 |
|
|
|
International Session 05 The Applicability of Hypofractionation for Breast, Prostate and Head and Neck Cancers: A Case-Based, Resource-Stratified Panel Discussion
|
1.25 |
|
|
|
International Session 04 IAEA - ASTRO Joint Session: Promises and Pitfalls of Proton Beam Therapy for New Adopters of Advanced Technology ? Global Perspectives
|
1.25 |
|
|
|
Panel 05 Mechanisms and Clinical Translation of FLASH-RT
|
1.25 |
|
|
|
Panel 06 AI Applications for Global Radiation Oncology
|
1.25 |
|
|
|
Panel 08 Genomics, Radiomics, and Radiogenomics for Lung Cancer Treatment Assessment in Radiation Therapy
|
1.25 |
|
|
|
Panel 07 New Patient-Focused Paradigms in Gynecologic Cancer
|
1.25 |
|
|
|
International Session 06 Chinese Refresher Course: Immunotherapy Beyond Anti-PD-1/L1
|
1.25 |
|
|
|
EDU 10 2021 Radiation Oncology Coding and Coverage Update
|
1.25 |
|
|
|
eContouring 03 eContouring for Head and Neck Cancer
|
1.25 |
|
|
|
SS 15 GI 01
|
1.25 |
|
|
|
PL 01 Plenary Session
|
1 |
|
|
|
SS 16 Biology 05 - Molecular Predictors of Prognosis and Response
|
1.25 |
|
|
|
SS 17 GYN 1 - Personalized Medicine in Gynecologic Cancers: Exploring Molecular Stratification and the Immune System
|
1.25 |
|
|
|
SS 18 Patient Safety
|
1.25 |
|
|
|
SS 21 Physics 06 - Imaging and Response Assessment
|
1.25 |
|
|
|
SS 23 Physics 07 - Delivery: Hardware Technologies and Novel Procedures
|
1.25 |
|
|
|
QP 12 GI 02 - Hypofractionation in GI Cancers
|
1 |
|
|
|
QP 10 HSR/Global Oncology 2 - Costs and Decisions
|
1 |
|
|
|
QP 11 Physics 05 - Imaging for Response Assessment and Outcome Analysis
|
1 |
|
|
|
QP 13 Breast 03
|
1 |
|
|
|
QP 14 Hematologic 2 - Integrating Radiotherapy in Curative Treatment for Hematologic Malignancies
|
1 |
|
|
|
Keynote Address I Keynote Address I - Closing the Cancer Divide AND Strengthening Health Systems: Interwoven Opportunities
|
1 |
|
|
|
SS 22 GU 04 - Prostate Dose, Volumes and Outcomes
|
1.25 |
|
|
|
ROI Luncheon ROI Session: Financial Planning: The SECURE Act and Its Impact on Your Future
|
1.25 |
|
|
|
CB 03 Cancer Breakthroughs 3 - Takeaways from the Major Oncology Meetings of 2020: Featuring ASCO and ASH
|
1 |
|
|
|
Panel 12 Indications of Medical Marijuana/Cannabinoids and Its Role in Cancer Therapy
|
1.25 |
|
|
|
Panel 11 German Radiation Oncology during National Socialism
|
1.25 |
|
|
|
Panel 14 Radiorecurrent and Metastatic Prostate Cancer: The Radiation Oncologist as the Quarterback
|
1.25 |
|
|
|
EDU 15 Stereotactic Radiotherapy in Management of Pediatric Malignancies
|
1.25 |
|
|
|
EDU 22 Underserved: The Urban/Rural Divide and Addressing Geographic Disparities in American Radiation Oncology
|
1.25 |
|
|
|
EDU 14 Combining Radiation and Immunotherapy for GU Malignancies: What Works, What Doesn't and What Next
|
1.25 |
|
|
|
Joint Session 03 The Intersection of Public Health and Radiation Oncology: What Radiation Oncologists Should Know About the FDA
|
1.25 |
|
|
|
EDU 16 Effectiveness, Cost, and Quality of Life in Lymphoma: Why RT Always Wins
|
1.25 |
|
|
|
EDU 21 Hypofractionation for Head and Neck Cancer
|
1.25 |
|
|
|
EDU 19 Glioblastoma Questions Asked and Answered: Case-based Tumor Board
|
1.25 |
|
|
|
Panel 13 Expanding the Indications for Radiation Therapy
|
1.25 |
|
|
|
Special Session 04 The Diverse Downstream Effects of Cytosolic DNA and dsRNA Sensing in Cancer
|
1.25 |
|
|
|
Special Session 02 ASTRO/NCI Diversity Symposium: Mitigating Implicit Bias in Radiation Oncology
|
1.25 |
|
|
|
Panel 09 Advancing Electronic Health Records Research in Radiation Oncology
|
1.25 |
|
|
|
Panel 15 Funding Your Research: Successful Strategies and Potential Pitfalls
|
1.25 |
|
|
|
EDU 13 Into the Heart! From Cardiac Avoidance to Treating the Heart: Insights from Malignancies to Arrhythmia
|
1.25 |
|
|
|
Panel 10 Peer Review Debate: Where Best To Invest?
|
1.25 |
|
|
|
eContouring 04 eContouring for Prostate Cancer
|
1.25 |
|
|
|
SS 28 Nursing and Supportive Care
|
1.25 |
|
|
|
SS 29 GI 03 - Biomarkers of Response in GI Cancers
|
1.25 |
|
|
|
SS 19 Late-breaking Special Session
|
1 |
|
|
|
SS 24 Patient Reported Outcomes/QoL/Survivorship - New Frontiers in Patient Reported Outcomes and Quality of Life
|
1.25 |
|
|
|
SS 25 Lung 02 - The Role of Radiotherapy in Oligometastasis/Stage IV Lung Cancer
|
1.25 |
|
|
|
SS 26 Biology 08 - Radiation Effects on Normal Tissue
|
1.25 |
|
|
|
SS 27 Physics 08 - Methodologies for Planning and Adaptation
|
1.25 |
|
|
|
SS 30 H&N 02 - Practical Head & Neck Radiotherapy
|
1.25 |
|
|
|
SS 31 Palliative Care 02 - From Palliation to Oligometastatic Disease: The Role of SBRT
|
1.25 |
|
|
|
SS 32 Biology 09 - Modulation of the Immune System and Tumor Microenvironment
|
1.25 |
|
|
|
QP 16 H&N 01 - Head & Neck in 2020
|
1 |
|
|
|
QP 19 Physics 09 - Motion Management
|
1 |
|
|
|
QP 20 Lung 03 - Novel Approaches to Non-small Cell Lung Cancer
|
1 |
|
|
|
QP 15 Biology 07 - Radiation and Immunotherapy
|
1 |
|
|
|
QP 18 Hematologic 3 - The Increasing Role of Radiotherapy in Relapsed/Refractory Disease and Palliation of Hematologic Malignancies
|
1 |
|
|
|
QP 17 Digital Health Innovation/Informatics 02 - Clinical Applications of Artificial Intelligence Session 2
|
1 |
|
|
|
Storytelling 04 Radiation Oncology in the Time of COVID
|
1.5 |
|
|
|
CB 04 Cancer Breakthroughs 4 - Takeaways from the Major Oncology Meetings of 2020: Featuring RSNA and AAPM
|
1 |
|
|
|
ST 04 Storytelling 04 - Overcoming Barriers to Radiation Oncology Access in Low-Resource Environments
|
1 |
|
|
|
SS 41 Late-breaking COVID-19 Scientific Session
|
1.25 |
|
|
|
Panel 19 Ethics and Big Data in Radiation Oncology
|
1.25 |
|
|
|
EDU 31 Immunology 101: Primer on Immunology, Mechanisms of Action of Immunotherapy, and Combinations with Radiation
|
1.25 |
|
|
|
Joint Session 04 Geriatric Oncology: What Do Radiation Oncologists Need to Know
|
1.25 |
|
|
|
EDU 29 Controversies in the Management of Adult Sarcomas
|
1.25 |
|
|
|
Panel 23 Daily Adaptive Planning Enables Ablative Radiation for Pancreatic Cancer
|
1.25 |
|
|
|
Panel 17 Lymphoma Crossing Borders ? Treatment Options Around the Globe
|
1.25 |
|
|
|
Panel 20 Breast Cancer in Women of African Heritage: Genetic and Socioeconomic Underpinnings of Health Disparities
|
1.25 |
|
|
|
EDU 28 Post-operative Management of Prostate Cancer
|
1.25 |
|
|
|
EDU 25 The Radiation Biology of Heavy Ion Radiation Therapy
|
1.25 |
|
|
|
EDU 24 Emerging and Re-emerging Topics in Brachytherapy
|
1.25 |
|
|
|
Workshop 06 Beyond Oligometastasis — Establishing and Implementing Metastatic Disease Program as a Distinct Specialty in Radiation Oncology
|
1.25 |
|
|
|
EDU 23 In Patients with a Long List of Previous Chemotherapy/Immunotherapy, How Safe Is It to Deliver Radiation?
|
1.25 |
|
|
|
Panel 22 Expanding Radiation Oncology Worldwide: A Review of Non-Profit Organization Initiatives and Panel Discussion on Opportunities for Engagement
|
1.25 |
|
|
|
EDU 04 Challenging Cases in Uterine Cancer
|
1.25 |
|
|
|
Panel 21 The Physics of FLASH Radiotherapy
|
1.25 |
|
|
|
EDU 26 Beyond TNM: Making Breast Radiotherapy Decisions Based on Tumor Biology
|
1.25 |
|
|
|
EDU 30 The Role of Stereotactic Radiotherapy in Renal Cell Carcinoma — Radioresistance or Resistance to Radiate?
|
1.25 |
|
|
|
Panel 18 Exosomes and Exosomal MicroRNAs in Radiation Therapy: Novel Assays for Treatment Personalization.
|
1.25 |
|
|
|
EDU 27 "Data Science for Dummies": A Step-By-Step Guide for Developing a Data Science Program
|
1.25 |
|
|
|
SS 33 Physics 10 - Planning: Algorithms and Optimization
|
1.25 |
|
|
|
SS 38 Biology 11 - Biologic Markers of Immune Response
|
1.25 |
|
|
|
SS 35 Physics 11 - Auto-segmentation and Imaging for Treatment Planning
|
1.25 |
|
|
|
SS 36 Lung 04 - Clinical Trials in Locally Advanced Non-small Cell Lung Cancer
|
1.25 |
|
|
|
SS 37 H&N 03 - Novel and Prospective Trials
|
1.25 |
|
|
|
QP 26 CNS 3 - Benign Tumors & Novel Biomarkers
|
1 |
|
|
|
QP 22 Pediatrics 03 - Changing the Paradigm for Pediatric Cancer Care
|
1 |
|
|
|
QP 21 CNS 2 - Brain Metastasis
|
1 |
|
|
|
QP 23 Biology 10 - Imaging and Normal Tissue Response
|
1 |
|
|
|
CT 01 Clinical Trials Session
|
1 |
|
|
|
QP 25 Physics 12 - Treatment Planning and Motion Management
|
1 |
|
|
|
SS 39 GYN 2 - Advancing the Therapeutic Ratio and Novel Therapies in Cervical Cancer
|
1.25 |
|
|
|
SS 40 Hematologic 4 - State-of-the-Art Image Guided Therapy in Lymphoma
|
1.25 |
|
|
|
SS 34 HSR/Global Oncology 3 - Healthcare Costs and Access to Care
|
1.25 |
|
|
|
Storytelling 06 ASTRO's COVID-19 Survey Results
|
1 |
|
|
|
Special Session 06 Special Session - COVID-19 and the Impact on the Healthcare Team
|
1 |
|
|
|